Chinese Health Watchdog Stands Firm on Quality of Domestic Generic Drugs Amid Rising Concerns

The Chinese National Medical Products Administration (NMPA) has recently issued a strong defense regarding the quality standards of local generic medications. This statement comes in light of growing scrutiny and skepticism towards the efficacy and safety of domestically produced pharmaceuticals. The regulatory body emphasized that ongoing rigorous quality control measures are in place to ensure that generic drugs meet international standards.

Continue reading

Insights from Sandoz CEO Richard Saynor on Ozempic, Big Pharma Struggles, and Political Influences

In a candid conversation, Richard Saynor, CEO of Sandoz, provided a deep dive into the complexities surrounding the pharmaceutical landscape, including the rising prominence of Ozempic, challenges facing the industry, and the influence of political figures such as Donald Trump. Saynor’s insights shed light on the evolving narratives within Big Pharma and the implications for patients, healthcare, and future drug development.

Continue reading